



March 5, 2007

## **Vertex Pharmaceuticals Announces Completion of Conversion of Outstanding 5.75% Convertible Senior Subordinated Notes due 2011**

CAMBRIDGE, Mass., Mar 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in connection with the previously announced redemption of its 5.75% Convertible Senior Subordinated Notes due 2011, holders of all of the outstanding notes converted their notes into shares of Vertex's common stock. The aggregate outstanding principal amount of the notes prior to the conversion was approximately \$59.6 million. In accordance with the terms of the indentures governing the notes, the notes were converted into common stock at a conversion rate of \$14.94 per share. As a result of these conversions, Vertex issued approximately 4.0 million shares of common stock, increasing its total shares outstanding to approximately 131 million.

### About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. Vertex's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Vertex's press releases are available at [www.vrtx.com](http://www.vrtx.com)

(VRTX-G)

SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated  
Lynne Brum, 617-444-6614  
Vice President, Strategic Communications  
or  
Michael Partridge, 617-444-6108  
Director, Corporate Communications  
or  
Lora Pike, 617-444-6755  
Manager, Investor Relations

Copyright Business Wire 2007

News Provided by COMTEX